(NASDAQ: MRKR) Marker Therapeutics's forecast annual revenue growth rate of 183.25% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Marker Therapeutics's revenue in 2025 is $5,696,123.On average, 1 Wall Street analysts forecast MRKR's revenue for 2025 to be $3,394,451, with the lowest MRKR revenue forecast at $3,394,451, and the highest MRKR revenue forecast at $3,394,451. On average, 1 Wall Street analysts forecast MRKR's revenue for 2027 to be $260,241,205, with the lowest MRKR revenue forecast at $260,241,205, and the highest MRKR revenue forecast at $260,241,205.
In 2028, MRKR is forecast to generate $1,654,228,877 in revenue, with the lowest revenue forecast at $1,654,228,877 and the highest revenue forecast at $1,654,228,877.